Patient demographic and clinical characteristics
| Characteristic . | All patients (N = 75) . |
|---|---|
| Evaluable for safety, n | 75 |
| Evaluable for efficacy, n | 69 |
| Age, median (range), y | 64 (26-86) |
| Sex, n (%) | |
| Male | 49 (65) |
| Female | 26 (35) |
| ECOG performance status, n (%) | |
| 0 | 21 (28) |
| 1 | 50 (67) |
| 2 | 4 (5) |
| CLL/SLL, n/N (%) | 22/75 (29) |
| Chromosome 17p deletion | 9/22 (41) |
| Aggressive B-NHL, n/N (%) | 29/75 (39) |
| DLBCL | 26/28 (93) |
| GCB | 16/26 (62) |
| Non-GCB | 10/26 (15) |
| Unknown | 6/26 (23) |
| MCL | 2/28 (7) |
| RT | 1/23 (4) |
| Indolent B-NHL, n/N (%) | 24/75 (32) |
| FL | 19/24 (79) |
| MZL | 5/24 (21) |
| Median previous therapies, n (range)/≥3 previous therapies, n | 3 (0-10)/43 |
| DLBCL | 3 (1-10)/18 |
| MCL | 4.5 (4-5)/2 |
| RT | 1 (1)/0 |
| CLL/SLL | 2 (0-7)/7 |
| FL | 4 (1-7)/14 |
| MZL | 2 (1-3)/2 |
| Previous therapy regimens, median (range), n (%) | 3 (0-10)* |
| Anthracycline-based therapy† | 59 (79) |
| BR or R-CVP | 39 (52) |
| Purine analogue-based therapy | 13 (17) |
| BTK inhibitor | 9 (12) |
| PI3K inhibitor | 4 (5) |
| Lenalidomide | 10 (13) |
| CAR-T therapy | 2 (3) |
| Transplantation | 12 (16) |
| Refractory to immediately prior therapy | 43 (57) |
| Previous exposure to anti-CD20 regimen, n (%) | 72 (96) |
| Refractory to previous anti-CD20 regimen | 39 (54) |
| ≥2 previous anti-CD20 regimens | 53 (71) |
| Characteristic . | All patients (N = 75) . |
|---|---|
| Evaluable for safety, n | 75 |
| Evaluable for efficacy, n | 69 |
| Age, median (range), y | 64 (26-86) |
| Sex, n (%) | |
| Male | 49 (65) |
| Female | 26 (35) |
| ECOG performance status, n (%) | |
| 0 | 21 (28) |
| 1 | 50 (67) |
| 2 | 4 (5) |
| CLL/SLL, n/N (%) | 22/75 (29) |
| Chromosome 17p deletion | 9/22 (41) |
| Aggressive B-NHL, n/N (%) | 29/75 (39) |
| DLBCL | 26/28 (93) |
| GCB | 16/26 (62) |
| Non-GCB | 10/26 (15) |
| Unknown | 6/26 (23) |
| MCL | 2/28 (7) |
| RT | 1/23 (4) |
| Indolent B-NHL, n/N (%) | 24/75 (32) |
| FL | 19/24 (79) |
| MZL | 5/24 (21) |
| Median previous therapies, n (range)/≥3 previous therapies, n | 3 (0-10)/43 |
| DLBCL | 3 (1-10)/18 |
| MCL | 4.5 (4-5)/2 |
| RT | 1 (1)/0 |
| CLL/SLL | 2 (0-7)/7 |
| FL | 4 (1-7)/14 |
| MZL | 2 (1-3)/2 |
| Previous therapy regimens, median (range), n (%) | 3 (0-10)* |
| Anthracycline-based therapy† | 59 (79) |
| BR or R-CVP | 39 (52) |
| Purine analogue-based therapy | 13 (17) |
| BTK inhibitor | 9 (12) |
| PI3K inhibitor | 4 (5) |
| Lenalidomide | 10 (13) |
| CAR-T therapy | 2 (3) |
| Transplantation | 12 (16) |
| Refractory to immediately prior therapy | 43 (57) |
| Previous exposure to anti-CD20 regimen, n (%) | 72 (96) |
| Refractory to previous anti-CD20 regimen | 39 (54) |
| ≥2 previous anti-CD20 regimens | 53 (71) |
BR, bendamustine/rituximab; CAR-T, chimeric antigen receptor T-cell; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; MCL, mantle cell lymphoma; R-CVP, rituximab/cyclophosphamide/vincristine sulfate/prednisone; RT, Richter’s transformation.
One patient was treatment-naive.
Anthracycline-based therapies included R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone), R-ICE (rituximab/ifosfamide/carboplatin/etoposide), R-EPOCH (rituximab/etoposide/prednisone/vincristine/cyclophosphamide/doxorubicine), and R-Gem/Ox (rituximab/gemcitabine/oxaliplatin).